Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model

Olivier Le Tilly, Philippe Gatault, Christophe Baron, Theodora Bejan‐Angoulvant, Matthias Büchler, Gilles Paintaud, David Ternant

Open source

DOI
10.1111/bcp.15235
Published
2022-02
Container
British Journal of Clinical Pharmacology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/bcp.15235,
  title = {Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model},
  author = {Olivier Le Tilly and Philippe Gatault and Christophe Baron and Theodora Bejan‐Angoulvant and Matthias Büchler and Gilles Paintaud and David Ternant},
  year = {2022},
  journal = {British Journal of Clinical Pharmacology},
  doi = {10.1111/bcp.15235},
  url = {https://doi.org/10.1111/bcp.15235}
}

RIS

TY  - JOUR
TI  - Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model
AU  - Olivier Le Tilly
AU  - Philippe Gatault
AU  - Christophe Baron
AU  - Theodora Bejan‐Angoulvant
AU  - Matthias Büchler
AU  - Gilles Paintaud
AU  - David Ternant
PY  - 2022
JO  - British Journal of Clinical Pharmacology
DO  - 10.1111/bcp.15235
UR  - https://doi.org/10.1111/bcp.15235
ER  - 

APA

Tilly, O. L., Gatault, P., Baron, C., Bejan‐Angoulvant, T., Büchler, M., Paintaud, G., & Ternant, D. (2022). Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15235

Source records